DE69526102D1 - Verwendung von [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2.] oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit - Google Patents

Verwendung von [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2.] oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit

Info

Publication number
DE69526102D1
DE69526102D1 DE69526102T DE69526102T DE69526102D1 DE 69526102 D1 DE69526102 D1 DE 69526102D1 DE 69526102 T DE69526102 T DE 69526102T DE 69526102 T DE69526102 T DE 69526102T DE 69526102 D1 DE69526102 D1 DE 69526102D1
Authority
DE
Germany
Prior art keywords
alpha
alzheimer
disease
pct
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526102T
Other languages
English (en)
Other versions
DE69526102T2 (de
Inventor
E Markwell
Julie Hawkins
W Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MINSTER PHARMACEUTICALS PLC, SAFFRON WALDEN, GB
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE69526102D1 publication Critical patent/DE69526102D1/de
Publication of DE69526102T2 publication Critical patent/DE69526102T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69526102T 1994-10-25 1995-10-17 Verwendung von [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2.] oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit Expired - Fee Related DE69526102T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421472A GB9421472D0 (en) 1994-10-25 1994-10-25 Novel methods
PCT/EP1995/004082 WO1996012486A1 (en) 1994-10-25 1995-10-17 Use of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta a4 formation in alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69526102D1 true DE69526102D1 (de) 2002-05-02
DE69526102T2 DE69526102T2 (de) 2002-10-31

Family

ID=10763350

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526102T Expired - Fee Related DE69526102T2 (de) 1994-10-25 1995-10-17 Verwendung von [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2.] oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit

Country Status (22)

Country Link
US (1) US5891887A (de)
EP (1) EP0786998B1 (de)
JP (1) JPH10509697A (de)
KR (1) KR100393365B1 (de)
CN (1) CN1085529C (de)
AT (1) ATE214926T1 (de)
AU (1) AU698695B2 (de)
BG (1) BG101500A (de)
BR (1) BR9509433A (de)
CZ (1) CZ287370B6 (de)
DE (1) DE69526102T2 (de)
DK (1) DK0786998T3 (de)
ES (1) ES2173977T3 (de)
GB (1) GB9421472D0 (de)
HK (1) HK1002057A1 (de)
HU (1) HUT77007A (de)
NO (1) NO312055B1 (de)
NZ (1) NZ295155A (de)
PT (1) PT786998E (de)
SK (1) SK50497A3 (de)
WO (1) WO1996012486A1 (de)
ZA (1) ZA958946B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU751607B2 (en) * 1995-07-29 2002-08-22 Smithkline Beecham Plc Method of treatment of dementia
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
IL138192A0 (en) * 1998-03-11 2001-11-25 Smithkline Beecham Plc Controlled release oral dosage forms
GB9815383D0 (en) * 1998-07-15 1998-09-16 Smithkline Beecham Plc Novel method of treatment
US6245884B1 (en) * 1998-10-16 2001-06-12 Vivian Y. H. Hook Secretases related to alzheimer's dementia
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219636T3 (es) * 1989-04-13 2004-12-01 Beecham Group P.L.C. Nuevos compuestos.
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
MX9300875A (es) * 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
GB9409705D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
EP0786998A1 (de) 1997-08-06
AU3843195A (en) 1996-05-15
GB9421472D0 (en) 1994-12-07
MX9703077A (es) 1997-07-31
HK1002057A1 (en) 1998-07-31
ZA958946B (en) 1996-08-20
CN1085529C (zh) 2002-05-29
WO1996012486A1 (en) 1996-05-02
DE69526102T2 (de) 2002-10-31
PT786998E (pt) 2002-09-30
NO971899D0 (no) 1997-04-24
CZ287370B6 (en) 2000-11-15
AU698695B2 (en) 1998-11-05
SK50497A3 (en) 1997-09-10
ES2173977T3 (es) 2002-11-01
NZ295155A (en) 2000-07-28
HUT77007A (hu) 1998-03-02
BG101500A (en) 1998-01-30
KR100393365B1 (ko) 2003-12-18
BR9509433A (pt) 1997-09-16
JPH10509697A (ja) 1998-09-22
CZ125197A3 (en) 1997-07-16
EP0786998B1 (de) 2002-03-27
DK0786998T3 (da) 2002-07-15
ATE214926T1 (de) 2002-04-15
CN1170365A (zh) 1998-01-14
US5891887A (en) 1999-04-06
NO971899L (no) 1997-04-24
KR970706816A (ko) 1997-12-01
NO312055B1 (no) 2002-03-11

Similar Documents

Publication Publication Date Title
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69132688T2 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
FI934983A (fi) Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
KR900015730A (ko) 정신장해 치료방해
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen
DE69526102T2 (de) Verwendung von [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2.] oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
HUP9904401A2 (hu) [R-(Z)]-alfa-(Metoxi-imino)-alfa-(1-aza-biciklo[2.2.2]okt-3-il)-acetonitril-monohidroklorid hatóanyag-tartalmú szabályozott kibocsátású dózisforma
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
SE8903529D0 (sv) Medical use
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0103149A2 (hu) Gyógyszerkészítmény Alzheimer-kór kezelésére
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
ATE339199T1 (de) Methoden zur kolikenbehandlung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MINSTER PHARMACEUTICALS PLC, SAFFRON WALDEN, GB

8339 Ceased/non-payment of the annual fee